Company Overview
About Alamar Biosciences
Alamar Biosciences is a Fremont, California-based life sciences company founded in 2020 with a focus on advancing proteomics through ultrasensitive biomarker detection technology. The company's flagship platform, NULISA (Nucleic acid-Linked Immuno-Sandwich Assay), enables researchers to simultaneously measure hundreds of protein biomarkers from very small sample volumes — including blood, cerebrospinal fluid, and other biological matrices — with sensitivity orders of magnitude beyond conventional assays like ELISA. This capability is critical for detecting disease-associated proteins at very early stages before symptoms manifest.
Business Model & Competitive Advantage
Alamar has raised over $140M in funding, including a $100M Series C round. The capital supports continued platform development, expansion of the NULISA panel library (covering neurodegeneration, oncology, cardiovascular, and inflammatory disease biomarkers), and commercialization into pharma, biotech, and academic research markets. The company's proximity to major Bay Area biotech clusters and its partnerships with leading academic medical centers accelerate adoption among translational researchers.
Competitive Landscape 2025–2026
The NULISA platform addresses a significant unmet need in precision medicine: most existing proteomic tools sacrifice either sensitivity or multiplex capability. NULISA achieves both — enabling low-abundance biomarker detection at scale. This positions Alamar competitively against established proteomics players like Olink (acquired by Thermo Fisher Scientific) and SomaScan (SomaLogic), while its high sensitivity profile makes it particularly relevant for neurodegenerative disease research (Alzheimer's, Parkinson's) where plasma biomarkers are present at extremely low concentrations.
Key Differentiators
Emerging Innovator
Alamar Biosciences is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Alamar Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alamar Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alamar Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alamar Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →